ReviewFrontiers in pharmacology2026
Direct NLRP3 inflammasome inhibitors for cardiovascular therapeutics: a comparative review of synthetic and natural candidates.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome has emerged as a critical mediator in cardiovascular diseases, connecting cholesterol crystals and metabolic danger signals to atherogenic inflammation, myocardial injury, and adverse remodeling. Using direct inhibitors that bind to NLRP3 has advantages over indirect strategies. These advantages include retaining the function of other inflammatory body sensors and the potential for oral treatment. Several synthetic compounds have progressed to clinical trials. Recently, NT-0796 demonstrated a significant reduction in C-reactive protein in obese patients with cardiovascular risk, and VTX2735 has entered Phase II trials for recurrent pericarditis. However, the clinical failure of MCC950 due to hepatotoxicity underscores persistent translational challenges in this field. Oridonin is the most rigorously validated natural product that covalently modifies NLRP3 at Cys279. However, most reported "natural NLRP3 inhibitors" did not bind biochemically. This review demonstrates a three-tier evidence classification that differentiates confirmed direct inhibitors from functional modulators. We critically explored the potential for cardiovascular applications and identified bioavailability limitations, biomarker gaps, and trial design challenges that require innovative solutions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.